Astellas Pharma（4503）

Issuer Code Long Term Short Term
Astellas Pharma 4503 AA+p/Negative

News ReleaseMore

Jul. 11, 2024
JCR Affirmed AA+p on Astellas Pharma; Revised Outlook to Negative
May. 01, 2023
Astellas Pharma to Acquire a U.S. Company for Approx. USD 5.9 Billion - Finances Will Deteriorate, but Immediate Rating Revision Is Not Necessary
Sep. 07, 2022
JCR Affirmed AA+p/Stable Long-term Issuer Rating on Astellas Pharma
Jun. 15, 2022
Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2022
Jun. 01, 2021
Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2021Member Only
Oct. 23, 2020
JCR Affirmed AA+p/Stable Long-term Issuer Rating on Astellas PharmaMember Only
Jun. 17, 2020
Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2020Member Only
Dec. 03, 2019
Astellas Pharma Acquires US Biotechnology Firm - Limited Impact on RatingMember Only
Sep. 11, 2019
JCR Affirmed AA+p/Stable Long-term Issuer Rating on Astellas PharmaMember Only
Jun. 25, 2019
Highlights of Major Pharmaceutical Companies' Financial Results for Fiscal Year Ended March 2019Member Only

Issuer ReportsMore

Jul. 18, 2017

Astellas Pharma

Issuer Reports
Jul. 27, 2016

Astellas Pharma

Issuer Reports

ESG Credit OutlookMore

Reports relating to IssuerMore

Rating Lists
Corporates
Financial Institutions
Public Sector
Structured Finance (Investment Corporations)
Structured Finance (Structured Finance Products)
Sovereigns and Supranationals